Business
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted
About this update from Q32 Bio Inc.
[{"type":"text","content":"- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted Albert Seymour, Ph.D., to Chief Executive Officer Driving Clinical Trials and Genetic Medicines Platform Forward for Patients - BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments. “We remain on track to provide an update from our pheEDIT and juMPStart clinical trials, including site initiations and enrollment status, by the end of this year,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “With our recent pipeline prioritization, which included devoting resources to our ongoing clinical trials and select preclinical programs, Homology extended its cash runway into the fourth quarter of 2024 through key milestones across all programs. We continue to progress HMI-104, our lead GTx-mAb development candidate, through IND-enabling studies and believe that our optimized in vivo gene therapy development candidate for MLD, which has demonstrated the ability to cross the blood-brain-barrier following a single I.V. administration in preclinical studies, is differentiated from other approaches and makes it an attractive program for us to partner. Our work to bring first-in-class genetic medicine candidates forward for patients is ongoing, and we look forward to sharing our continued progress.” Third Quarter 2022 and Recent Highlights Announced a pipeline prioritization, which included shifting resources from the pheNIX gene therapy trial evaluating HMI-102 for phenylketonuria (PKU) and pausing enrollment to focus on generating data from the pheEDIT clinical trial that is evaluating in vivo gene editing candidate HMI-103 for PKU. The mechanism of action of this gene editing candidate has the potential to treat adults and ultimately pediatric patients.Continued to advance the juMPStart clinical trial evaluating in vivo gene therapy candidate HMI-203 for MPS II, or Hunter syndrome. Homology remains on track to provide an update on enrollment and site status for this trial and the pheEDIT trial by the end of this year.Continued to advance IND-enabling studies of HM...